Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
58
BUHPF Quote, Financials, Valuation and Earnings
Last price:
$5.35
Seasonality move
:
1.81%
Day range:
$5.35 - $5.35
52-week range:
$4.75 - $8.40
Dividend yield:
2.8%
P/E ratio:
90.83x
P/S ratio:
5.70x
P/B ratio:
4.99x
Volume:
--
Avg. volume:
17
1-year change:
-36.31%
Market cap:
$4.3B
Revenue:
$729.3M
EPS (TTM):
$0.06
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NIVF
NewGenIVF Group Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
$5.35 | -- | $4.3B | 90.83x | $0.06 | 2.8% | 5.70x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
$0.61 | -- | $9.6B | 74.69x | $0.01 | 3.74% | 3.11x |
|
CVM
CEL-SCI Corp.
|
$4.91 | $42.50 | $14.9M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
|
NIVF
NewGenIVF Group Ltd.
|
$0.90 | -- | $1.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
0.08% | 0.217 | 0.02% | 4.40x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
7.11% | -0.653 | 2.09% | 1.12x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NIVF
NewGenIVF Group Ltd.
|
-- | 0.341 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
-- | $68.7M | 26.98% | 27.01% | 38.69% | $36.6M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
-- | $165.3M | 14.38% | 15.71% | 20.2% | $129.4M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NIVF
NewGenIVF Group Ltd.
|
-- | -- | -- | -- | -- | -- |
Bumrungrad Hospital Public Co., Ltd. vs. Competitors
-
Which has Higher Returns BUHPF or AIM?
AIM ImmunoTech has a net margin of 30.84% compared to Bumrungrad Hospital Public Co., Ltd.'s net margin of -10571.43%. Bumrungrad Hospital Public Co., Ltd.'s return on equity of 27.01% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital BUHPFBumrungrad Hospital Public Co., Ltd.52.46% -- $887.3M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About BUHPF or AIM?
Bumrungrad Hospital Public Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Bumrungrad Hospital Public Co., Ltd., analysts believe AIM ImmunoTech is more attractive than Bumrungrad Hospital Public Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BUHPFBumrungrad Hospital Public Co., Ltd.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is BUHPF or AIM More Risky?
Bumrungrad Hospital Public Co., Ltd. has a beta of -0.048, which suggesting that the stock is 104.845% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock BUHPF or AIM?
Bumrungrad Hospital Public Co., Ltd. has a quarterly dividend of $0.06 per share corresponding to a yield of 2.8%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital Public Co., Ltd. pays 51.12% of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend. Bumrungrad Hospital Public Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUHPF or AIM?
Bumrungrad Hospital Public Co., Ltd. quarterly revenues are $181.9M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Bumrungrad Hospital Public Co., Ltd.'s net income of $56.1M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Bumrungrad Hospital Public Co., Ltd.'s price-to-earnings ratio is 90.83x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital Public Co., Ltd. is 5.70x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUHPFBumrungrad Hospital Public Co., Ltd.5.70x 90.83x $181.9M $56.1M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns BUHPF or BDULF?
Bangkok Dusit Medical Services Public Co. Ltd. has a net margin of 30.84% compared to Bumrungrad Hospital Public Co., Ltd.'s net margin of 15.48%. Bumrungrad Hospital Public Co., Ltd.'s return on equity of 27.01% beat Bangkok Dusit Medical Services Public Co. Ltd.'s return on equity of 15.71%.
Company Gross Margin Earnings Per Share Invested Capital BUHPFBumrungrad Hospital Public Co., Ltd.52.46% -- $887.3M BDULFBangkok Dusit Medical Services Public Co. Ltd.37.03% -- $3.4B -
What do Analysts Say About BUHPF or BDULF?
Bumrungrad Hospital Public Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Bangkok Dusit Medical Services Public Co. Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Bumrungrad Hospital Public Co., Ltd. has higher upside potential than Bangkok Dusit Medical Services Public Co. Ltd., analysts believe Bumrungrad Hospital Public Co., Ltd. is more attractive than Bangkok Dusit Medical Services Public Co. Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BUHPFBumrungrad Hospital Public Co., Ltd.0 0 0 BDULFBangkok Dusit Medical Services Public Co. Ltd.0 0 0 -
Is BUHPF or BDULF More Risky?
Bumrungrad Hospital Public Co., Ltd. has a beta of -0.048, which suggesting that the stock is 104.845% less volatile than S&P 500. In comparison Bangkok Dusit Medical Services Public Co. Ltd. has a beta of -0.025, suggesting its less volatile than the S&P 500 by 102.513%.
-
Which is a Better Dividend Stock BUHPF or BDULF?
Bumrungrad Hospital Public Co., Ltd. has a quarterly dividend of $0.06 per share corresponding to a yield of 2.8%. Bangkok Dusit Medical Services Public Co. Ltd. offers a yield of 3.74% to investors and pays a quarterly dividend of $0.01 per share. Bumrungrad Hospital Public Co., Ltd. pays 51.12% of its earnings as a dividend. Bangkok Dusit Medical Services Public Co. Ltd. pays out 74.55% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUHPF or BDULF?
Bumrungrad Hospital Public Co., Ltd. quarterly revenues are $181.9M, which are smaller than Bangkok Dusit Medical Services Public Co. Ltd. quarterly revenues of $826.7M. Bumrungrad Hospital Public Co., Ltd.'s net income of $56.1M is lower than Bangkok Dusit Medical Services Public Co. Ltd.'s net income of $127.9M. Notably, Bumrungrad Hospital Public Co., Ltd.'s price-to-earnings ratio is 90.83x while Bangkok Dusit Medical Services Public Co. Ltd.'s PE ratio is 74.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital Public Co., Ltd. is 5.70x versus 3.11x for Bangkok Dusit Medical Services Public Co. Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUHPFBumrungrad Hospital Public Co., Ltd.5.70x 90.83x $181.9M $56.1M BDULFBangkok Dusit Medical Services Public Co. Ltd.3.11x 74.69x $826.7M $127.9M
-
Which has Higher Returns BUHPF or CVM?
CEL-SCI Corp. has a net margin of 30.84% compared to Bumrungrad Hospital Public Co., Ltd.'s net margin of --. Bumrungrad Hospital Public Co., Ltd.'s return on equity of 27.01% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital BUHPFBumrungrad Hospital Public Co., Ltd.52.46% -- $887.3M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About BUHPF or CVM?
Bumrungrad Hospital Public Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Bumrungrad Hospital Public Co., Ltd., analysts believe CEL-SCI Corp. is more attractive than Bumrungrad Hospital Public Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BUHPFBumrungrad Hospital Public Co., Ltd.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is BUHPF or CVM More Risky?
Bumrungrad Hospital Public Co., Ltd. has a beta of -0.048, which suggesting that the stock is 104.845% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock BUHPF or CVM?
Bumrungrad Hospital Public Co., Ltd. has a quarterly dividend of $0.06 per share corresponding to a yield of 2.8%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital Public Co., Ltd. pays 51.12% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. Bumrungrad Hospital Public Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUHPF or CVM?
Bumrungrad Hospital Public Co., Ltd. quarterly revenues are $181.9M, which are larger than CEL-SCI Corp. quarterly revenues of --. Bumrungrad Hospital Public Co., Ltd.'s net income of $56.1M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Bumrungrad Hospital Public Co., Ltd.'s price-to-earnings ratio is 90.83x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital Public Co., Ltd. is 5.70x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUHPFBumrungrad Hospital Public Co., Ltd.5.70x 90.83x $181.9M $56.1M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns BUHPF or IGC?
IGC Pharma, Inc. has a net margin of 30.84% compared to Bumrungrad Hospital Public Co., Ltd.'s net margin of -953.4%. Bumrungrad Hospital Public Co., Ltd.'s return on equity of 27.01% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital BUHPFBumrungrad Hospital Public Co., Ltd.52.46% -- $887.3M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About BUHPF or IGC?
Bumrungrad Hospital Public Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than Bumrungrad Hospital Public Co., Ltd., analysts believe IGC Pharma, Inc. is more attractive than Bumrungrad Hospital Public Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BUHPFBumrungrad Hospital Public Co., Ltd.0 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is BUHPF or IGC More Risky?
Bumrungrad Hospital Public Co., Ltd. has a beta of -0.048, which suggesting that the stock is 104.845% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock BUHPF or IGC?
Bumrungrad Hospital Public Co., Ltd. has a quarterly dividend of $0.06 per share corresponding to a yield of 2.8%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital Public Co., Ltd. pays 51.12% of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend. Bumrungrad Hospital Public Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUHPF or IGC?
Bumrungrad Hospital Public Co., Ltd. quarterly revenues are $181.9M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Bumrungrad Hospital Public Co., Ltd.'s net income of $56.1M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Bumrungrad Hospital Public Co., Ltd.'s price-to-earnings ratio is 90.83x while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital Public Co., Ltd. is 5.70x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUHPFBumrungrad Hospital Public Co., Ltd.5.70x 90.83x $181.9M $56.1M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
-
Which has Higher Returns BUHPF or NIVF?
NewGenIVF Group Ltd. has a net margin of 30.84% compared to Bumrungrad Hospital Public Co., Ltd.'s net margin of --. Bumrungrad Hospital Public Co., Ltd.'s return on equity of 27.01% beat NewGenIVF Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BUHPFBumrungrad Hospital Public Co., Ltd.52.46% -- $887.3M NIVFNewGenIVF Group Ltd.-- -- -- -
What do Analysts Say About BUHPF or NIVF?
Bumrungrad Hospital Public Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand NewGenIVF Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 8253.75%. Given that NewGenIVF Group Ltd. has higher upside potential than Bumrungrad Hospital Public Co., Ltd., analysts believe NewGenIVF Group Ltd. is more attractive than Bumrungrad Hospital Public Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BUHPFBumrungrad Hospital Public Co., Ltd.0 0 0 NIVFNewGenIVF Group Ltd.0 0 0 -
Is BUHPF or NIVF More Risky?
Bumrungrad Hospital Public Co., Ltd. has a beta of -0.048, which suggesting that the stock is 104.845% less volatile than S&P 500. In comparison NewGenIVF Group Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BUHPF or NIVF?
Bumrungrad Hospital Public Co., Ltd. has a quarterly dividend of $0.06 per share corresponding to a yield of 2.8%. NewGenIVF Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital Public Co., Ltd. pays 51.12% of its earnings as a dividend. NewGenIVF Group Ltd. pays out -- of its earnings as a dividend. Bumrungrad Hospital Public Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUHPF or NIVF?
Bumrungrad Hospital Public Co., Ltd. quarterly revenues are $181.9M, which are larger than NewGenIVF Group Ltd. quarterly revenues of --. Bumrungrad Hospital Public Co., Ltd.'s net income of $56.1M is higher than NewGenIVF Group Ltd.'s net income of --. Notably, Bumrungrad Hospital Public Co., Ltd.'s price-to-earnings ratio is 90.83x while NewGenIVF Group Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital Public Co., Ltd. is 5.70x versus -- for NewGenIVF Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUHPFBumrungrad Hospital Public Co., Ltd.5.70x 90.83x $181.9M $56.1M NIVFNewGenIVF Group Ltd.-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
